Novo Nordisk Pharmaceuticals Pty Ltd.

丹麦诺和诺德（NYSE：NVO）发布了2023年上半年（2023H1）财报，该公司2023H1的销售额同比增长30%（按固定汇率计算，下同），达到1077亿丹麦克朗（159亿美元），这一增长主要由GLP-1药物和减肥药物驱动。该公司的糖尿病和肥胖护理业务增长了37%，达到990亿丹麦克朗（146亿美元）。其中，GLP-1糖尿病产品同比增长50%，达到547亿丹麦克朗（81亿美元），而肥胖护理产品同比增长157%，达到182亿挪威克朗（27亿美元）。相比之下，该公司胰岛素产品组合的销售额同比下降了8%，至247亿丹麦克朗（37亿美元）。GLP-1药物Wegovy推动中国暴涨按地区划分，诺和诺德在美国的销售额增长了42%，在EMEA（欧洲、中东和非洲）地区增长了19%，在中国增长了12%，在世界其他地区增长了18%。在中国，总收入达到89亿丹麦克朗（13.1亿美元），其中GLP-1药物的销售额增长了97%，达到31亿挪威克朗（4.57亿美元）。GLP-1药物在中国糖尿病市场的份额从一年前的1.6%上升到3.0%。另一方面，中国胰岛素销售额同比下降11%，至48亿丹麦克朗（7.09亿美元）。仅第二季度，中国市场收入同比增长35%，达到44.6亿丹麦克朗（6.58亿美元）。诺和诺德首席财务官Karsten Knudsen指出，“从去年5月开始”，公司开始消减带量采购（VBP）对胰岛素产品的影响，中国市场的业绩令人欣慰。特别是，第二季度超过30%的增长“非常令人印象深刻”，反映了“创新的价值”。其中，Ozenpic（司美格鲁肽）、诺和益（利拉鲁肽，德谷胰岛素）和诺和佳（德谷胰岛素，门冬胰岛素）等新产品推动了市场增长。点击 阅读原文 申请体验GBI SOURCE全球药品数据库

精彩内容7月4日华东医药发布公告称，全资子公司杭州中美华东制药申报的利拉鲁肽注射液肥胖或超重适应症的上市许可申请获得批准，中美华东为国内首家同时拥有该产品糖尿病适应症及肥胖或超重适应症批文的药企。图1：中美华东最新获批的产品情况来源：NMPA官网公告中提到，利拉鲁肽注射液的原研企业为丹麦诺和诺德公司，其糖尿病适应症于2009年获得EMA批准，2010年获得FDA批准，2011年获批进入国内市场。该产品的肥胖或超重适应症于2014年获得FDA批准，2015年获得EMA批准，目前尚未在国内获批。图2：利拉鲁肽注射液的全球销售情况（单位：百万丹麦克朗）来源：米内网跨国上市公司数据库米内网数据显示，近几年利拉鲁肽注射液肥胖或超重适应症的全球销售额快速攀升，2022年超过了106.76亿丹麦克朗（按即时汇率约15.59亿美元）。图3：中美华东利拉鲁肽注射液的报产情况来源：米内网中国申报进度（MED）数据库中美华东于2021年提交了的利拉鲁肽注射液糖尿病适应症的上市申请并于2023年3月获批上市，据悉该产品目前已正式实现商业化上市销售，并在全国各省积极开展挂网和进院的工作。该产品肥胖或超重适应症于2022年7月提交上市申请，如今正式获批。中美华东是国内首家同时拥有利拉鲁肽注射液糖尿病适应症及肥胖或超重适应症批文的药企。截至目前，公司在利拉鲁肽注射液项目（含糖尿病适应症、肥胖或超重适应症）的研发投入超过3.2亿元。公告中提到，在肥胖或体重超重患者的治疗领域，中美华东已有产品奥利司他胶囊，通过近几年在国内市场的销售和推广，已积累一定的学术推广基础和市场资源。此次公司获得利拉鲁肽注射液（肥胖或超重适应症）药品注册证书，将进一步补充公司内分泌领域产品线，与现有的奥利司他胶囊实现临床和院内外市场的协同互补，为后续公司GLP-1类产品的上市奠定良好的市场基础。资料来源：NMPA官网、公司公告、米内网数据库注：数据统计截至7月5日。本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

Novo Nordisk today announced plans to invest 15.9 billion Danish kroner starting in 20231 to expand an existing Active Pharmaceutical Ingredient (API) production facility in Denmark for the future portfolio within serious chronic diseases. The investment comes as Novo Nordisk marks the 100th anniversary of its founding in Denmark, where 21,000-plus employees – approximately half of the company's global workforce2 - still work today. The majority of these employees work at various production sites. The investment in Hillerød, Denmark will create additional production capacity and increase Novo Nordisk’s ability to meet future market demands and be a key enabler for Novo Nordisk to develop its future clinical late-phase product portfolio. “This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide,” said Henrik Wulff, executive vice president of Product Supply, Quality & IT. “The investment announced today confirms Hillerød and Denmark as cornerstones in our global footprint, and I would like to take this opportunity to thank the Danish Government and Parliament for their continued focus on ensuring good and stable infrastructure and supplies – allowing us to continue to expand our production capacity to the benefit of patients living with serious chronic diseases. The new facility – which will be approximately 65,000m2 – will be designed as a multi-product facility, with maximum flexibility to accommodate new processes and displaying state-of-the-art technology and working environment. As a future-proof and cost-effective facility, the construction will focus on delivering the highest quality to patients worldwide in an efficient and environmentally sustainable way. This will be done by designing optimal and compact process flows allowing a substantial reduction of water and energy consumption3. Construction is underway and the facility is expected to start producing API by early 2029. This project is expected to create 340 new jobs when construction is completed, and the facility is fully equipped. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 57,100 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube. 1 A portion of this investment is included in the DKK 25 billion capital expenditure announced in connection with Novo Nordisk full year results in February 2023. The additional amount will be invested through the next six years. 2 21.000 full-time positions in Denmark in 2022, representing 40% of all positions globally 3 Internal calculations show that production in the future facility will reduce water consumption with more than 40% and energy consumption with more than 1/3 compared to similar API processes in other facilities. The content above comes from the network. if any infringement, please contact us to modify.